-
公开(公告)号：US20230045783A9
公开(公告)日：2023-02-09
申请号：US17468103
申请日：2021-09-07
Applicant: Exelixis, Inc.
Inventor： Dana T. Aftab , Gisela Schwab , Colin Hessel , Christian Scheffold , Steven Lacy , Dale Miles , Alan Arroyo , Mark Dean
Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
-
公开(公告)号：US20220056138A1
公开(公告)日：2022-02-24
申请号：US17519327
申请日：2021-11-04
Applicant: Exelixis, Inc.
Inventor： Gisela Schwab , Christian Scheffold , Colin Hessel
IPC: C07K16/28 , A61P35/04 , A61K31/47 , A61K39/395 , A61K45/06
Abstract: This invention relates to the combination of cabozantinib and atezolizumab to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma.
-
公开(公告)号：US20220000857A1
公开(公告)日：2022-01-06
申请号：US17468103
申请日：2021-09-07
Applicant: Exelixis, Inc.
Inventor： Dana T. Aftab , Gisela Schwab , Colin Hessel , Christian Scheffold , Steven Lacy , Dale Miles , Alan Arroyo , Mark Dean
Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
-
公开(公告)号：US11141413B2
公开(公告)日：2021-10-12
申请号：US16093426
申请日：2017-04-17
Applicant: Exelixis, Inc.
Inventor： Dana T. Aftab , Gisela Schwab , Colin Hessel , Christian Scheffold , Steven Lacy , Dale Miles , Alan Arroyo , Mark Dean
Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
-
公开(公告)号：US20240350477A1
公开(公告)日：2024-10-24
申请号：US18359214
申请日：2023-07-26
Applicant: Exelixis, Inc.
Inventor： Dana T. Aftab , Gisela Schwab , Colin Hessel , Christian Scheffold , Steven Lacy , Dale Miles , Alan Arroyo , Mark Dean
CPC classification number: A61K31/47 , A61K9/2009 , A61K9/2018 , A61K9/2054 , A61K9/2866 , A61K31/16 , A61P35/00
Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
-
Patent Agency Ranking
公开(公告)号：US20230301979A1
公开(公告)日：2023-09-28
申请号：US18018805
申请日：2021-07-29
Applicant: Exelixis, Inc.
Inventor： Gisela Schwab , Christian Scheffold , Colin Chong , Ssucheng Jeff Hsu , Peter Lamb , Peiwen Yu
CPC classification number: A61K31/47 , C07K16/2818 , C07K16/2827 , A61K38/2013 , A61K45/06 , A61P35/04 , C07B2200/13
Abstract: The present invention relates to combinations comprising a checkpoint inhibitor and a c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of the free base of Compound 1, as well as crystalline forms of salts of Compound 1, in combination with a checkpoint inhibitor. The invention also relates to pharmaceutical compositions comprising these combinations. The invention further relates to methods of treating cancer by administering Compound 1 as a single agent or a combination described herein.
-
公开(公告)号：US20190352403A1
公开(公告)日：2019-11-21
申请号：US16479143
申请日：2018-01-19
Applicant: Exelixis, Inc.
Inventor： Gisela Schwab , Christian Scheffold , Colin Hessel
IPC: C07K16/28 , A61K31/47 , A61K39/395 , A61K45/06 , A61P35/04
Abstract: This invention relates to the combination of cabozantinib and atezolizumab to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma.
-
公开(公告)号：US20220401433A1
公开(公告)日：2022-12-22
申请号：US17888356
申请日：2022-08-15
Applicant: Exelixis, Inc.
Inventor： Dana T. Aftab , Gisela Schwab , Colin Hessel , Christian Scheffold , Steven Lacy , Dale Miles , Alan Arroyo , Mark Dean
Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
-
公开(公告)号：US11198731B2
公开(公告)日：2021-12-14
申请号：US16479143
申请日：2018-01-19
Applicant: Exelixis, Inc.
Inventor： Gisela Schwab , Christian Scheffold , Colin Hessel
Abstract: This invention relates to the combination of cabozantinib and atezolizumab to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma.
-
公开(公告)号：US20190209547A1
公开(公告)日：2019-07-11
申请号：US16093426
申请日：2017-04-17
Applicant: Exelixis, Inc.
Inventor： Dana T. Aftab , Gisela Schwab , Colin Hessel , Christian Scheffold , Steven Lacy , Dale Miles , Alan Arroyo , Mark Dean
CPC classification number: A61K31/47 , A61K9/2009 , A61K9/2018 , A61K9/2054 , A61K9/2866 , A61K31/16 , A61P35/00
Abstract: The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.019 seconds)
